BMI View: Wide-scale changes to the regulatory environment of Ukraine's pharmaceutical sector will
increase its attractiveness to multinational pharmaceutical manufactures. The introduction of reference
pricing will aid in improving medicine affordability and accessib ..."
BMI View: The burden of chronic diseases in Ukraine will remain dominant in the country over the next
fifteen years, and the country's continuing war will contribute to the country's poor epidemiological profile.
The country's pharmaceutical market will maintain stren ..."
BMI View: Ukraine's negative pharmaceutical trade balance will remain and continue to widen to 2019 as
the country's political and economic landscapes hamper its local business development. A rising demand
for medicines will force the Ukraine to continue seeking its m ..."
BMI View: Ukraine's pharmaceutical market will continue to experience inflationary dynamics in 2015, as
the impact of the country's economic instability and the Ukrainian hryvnia's depreciation contribute to drug
price inflation. We expect market share will further sh ..."
BMI View: The Ukrainian pharmaceutical market will continue to feel the impact of the country's parlous
economic state in 2015. Local currency growth in the Ukrainian pharmaceutical market during the year
will be driven by price inflation rather than actual volume dem ..."
BMI View: In the short-term, Ukraine's pharmaceutical market will continue to suffer from the impact of
its tenuous economic position, the civil unrest in the economic heartlands of Eastern Ukraine and the severe
erosion of consumer purchasing power resulting from a s ..."
BMI View: In line with our view, price inflation is contributing to pharmaceutical volume drop-off in
Ukraine. Sales have risen in local currency terms, but declined in real terms. We see the remainder of 2014
and 2015 as being particularly challenging within Ukraine ..."
BMI View: Ukraine is currently experiencing geopolitical tension with its neighbour Russia, which is
actively fomenting unrest in the east of Ukraine. In 2014, owing to the severe devaluation of the hryvnia in
the country, drugmakers can expect a challenging business ..."
BMI View: Ukraine remains a risky pharmaceutical market, despite having once been one of the most
attractive markets in the Central and Eastern European region. In 2014, owing to the distressed economic
situation in the country, drugmakers can expect a challenging bus ..."
BMI View: Ukraine remains a promising yet risky pharmaceutical market. In 2014, owing to the unstable
political and economic situation in the country, drugmakers can expect a challenging business environment
and capital outflow restrictions. Exchange rate risks present consider ..."